secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001171843-24-006360
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics Q3 2024 net loss narrows to $1.8M; cash at $6.3M
------------------------------------------------------------------

- Net loss of $1.8M ($0.05 per share) improved from $5.1M ($0.15) in Q3 2023.
- Cash and equivalents $6.3M; operations used $3.0M in Q3, down from $4.2M YoY.
- R&D expenses fell to $541K from $3.4M; total operating loss $1.9M vs $5.2M.
- Phase 2 gastric cancer trial data expected at a major conference in early 2025.
- Dr. Robert Kadlec joined board; new collaboration with Autonomous Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184324006360/0001171843-24-006360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184324006360/f8k_111424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer